ACT's MA09-hRPE cells gets US FDA orphan drug status to treat Stargardt's Macular Dystrophy
Friday, March 05, 2010 17:00 IST Worcester
Advanced Cell Technology, Inc, (ACT) a biotechnology company applying cellular technology in the field of regenerative medicine, announced that the US Food and Drug Administration (FDA)
